Entered into a convertible bond with warrants issuance program with Cantor Fitzgerald Europe. Combined issuance of the 4th\u20136th series of convertible bonds with warrants and third-party allotment of new shares to Daisuke Gomi and Kaya Holdings to secure short-term financing: approximately 561 million yen from the warrants-bearing convertible bonds and approximately 850 million yen from new shares. Conversion price fixed at 0.9\u00d7 the previous trading day’s closing price, with adjustments for splits, etc. Structure is designed to strengthen capital while mitigating dilution. Disclosure includes risk of potential insolvency.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Carna Biosciences, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4572-20260928-01.pdf","jir_short_summary":"Entered into a convertible bond with warrants issuance program with Cantor Fitzgerald Europe. Combined issuance of the 4th\u20136th series of convertible bonds with warrants and third-party allotment of new shares to Daisuke Gomi and Kaya Holdings to secure short-term financing: approximately 561 million yen from the warrants-bearing convertible bonds and approximately 850 million yen from new shares. Conversion price fixed at 0.9\u00d7 the previous trading day's closing price, with adjustments for splits, etc. Structure is designed to strengthen capital while mitigating dilution. Disclosure includes risk of potential insolvency.","jir_summary":"### Overview of Capital Policy\nThis IR announces that the company has established a convertible bond with warrants issuance program with Cantor Fitzgerald Europe as the allottee, and plans fundraising through issuance of the 4th series convertible bond with warrants and subsequent 5th and 6th series allotments. Immediate capital enhancement is combined with share issuance, raising approximately 561 million yen via convertible bonds with warrants and approximately 850 million yen via new shares. The conversion price is fixed at 0.9 times the previous trading day's closing price, with adjustments for splits, etc., and dilution impact is distributed over three issuances. The third-party allotments will be made to Daisuke Gomi and Kaya Holdings.\n\n### Planned Use of Funds and Risks\nProceeds will be allocated to clinical development costs, preclinical development costs, and working capital to strengthen opportunities for clinical development out-licensing. However, these convertible bonds with warrants will create redemption obligations until maturity and involve potential dilution and impact on the share price. The structure aims to limit dilution for existing shareholders, and redemption of the convertible bonds may be considered if favorable conditions are obtained in the future. The plan seeks to balance long-term funding security with financial soundness.","jir_financial_highlights":"Total amount of new shares issued by third-party allotment: 850,081,050 yen (Unknown)\nAmount of convertible bonds with warrants by third-party allotment (4th series): 187,200,000 yen (Unknown)\nTotal number of new shares allotted (Daisuke Gomi 1,709,500 shares + Kaya Holdings 366,400 shares): 2,075,900 shares (Unknown)","jir_category":"","jir_hashtags":"#CarnaBiosciences, #CapitalPolicy","jir_key_figures":"850,081,050 yen: Amount of funds to be raised through this third-party allotment of new shares\n561,600,000 yen: Total amount of payments for these convertible bonds with warrants\n1,709,500 shares + 366,400 shares: Number of shares to be allotted in this new share allotment","jir_meta_title":"Carna Biosciences, Inc. - Notice on Capital Policy\uff5c2026-09-28","jir_meta_description":"Carna Biosciences announced the establishment of a convertible bond with warrants issuance program and a third-party allotment of new shares. Overview of measures to enhance capital flexibility, mitigate dilution, and intended use of funds.","jir_og_title":"Carna Biosciences Notice on Capital Policy","jir_og_description":"Overview of the establishment of a convertible bond with warrants issuance program and third-party allotment of new shares, explaining the purpose of fundraising and dilution mitigation measures.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-123864","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n